WM

Widya Mulyasasmita

Co-Founder, Managing Partner at BEVC

United States

Invests in

  • Min Investment:

    $25,000,000.00
  • Max Investment:

    $60,000,000.00
  • Target Investment:

    $25,000,000.00

Work Experience

2023

  • Co-Founder, Managing Partner

    2023

    Venture Capital firm investing in early stage companies at the intersection of science, engineering, and computation. www.bevc.com

  • Founding Advisor

    2020

    Democratizing single cell biotechnology. Team is hiring! www.partillion.com

  • Board of Directors

    2022 - 2023

2022 - 2023

  • Investor and Board Observer

    2022 - 2023

2021 - 2023

  • Sr. Principal, Healthcare

    2021 - 2023

  • Investor and Board Observer

    2021 - 2023

2021 - 2023

  • Board of Directors

    2021 - 2023

  • Vice President

    2020 - 2021

    Red Tree VC invests in early stage companies developing therapeutics addressing significant unmet needs in oncology, neurology, and immunology. Investor & Board Observer at: Acrigen Bioscience, Excellergy, Magnus Medical, Virsti Therapeutics

2020 - 2021

  • Investor and Board Observer

    2020 - 2021

2018 - 2020

  • Chief Business Officer (Founding Team)

    2018 - 2020

    InterVenn Biosciences leverages mass spectrometry and AI/ML to decode the human glycoproteome as a rich source of biological insight, to advance personalized, predictive, and preventative care. https://intervenn.com